IHS Chemical Week

Regions :: North America :: U.S.

Lonza to Supply Stem Cell Therapy Drug to Maryland Biotech Firm

11:27 AM MDT | July 14, 2008 | Alex Scott

Lonza says it has secured a deal with biotech firm Osiris Therapeutics (Columbia, MD) to manufacture what it says could be the world’s first stem cell drug. The agreement calls for Lonza to manufacture Osiris’s Prochymal stem cell therapy, which is being evaluated in phase III clinical trials for three medical applications including Crohn’s disease. Lonza says it will invest “millions of dollars” to build a Prochymal facility at its Walkersville, MD site. Financial terms were not disclosed. von Hippel: A focus on profitable products...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa